News - Hematology, CSL Limited

Filter

Current filters:

HematologyCSL Limited

Popular Filters

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Australia’s CSL posts solid half-year results

Australia’s CSL posts solid half-year results

13-02-2014

Australian blood products and vaccine maker CSL reported a 3% rise in net profit to $646 million (all…

CSL LimitedFinancialHematologyPharmaceuticalVaccines

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

08-12-2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the…

BayerCardio-vascularCSL BehringCSL LimitedEuropeHelixateHematologyKogenatePharmaceuticalRegulation

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL

05-12-2013

Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

CSL settles US antitrust class action litigation

CSL settles US antitrust class action litigation

09-10-2013

Australian blood products and vaccine maker CSL has signed an agreement to settle the US antitrust class…

CSL LimitedFinancialHematologyLegalNorth AmericaPharmaceutical

Back to top